The students presented on the anti-fibrotic effects of azithromycin (AZT) on lung fibroblasts from patients with idiopathic pulmonary fibrosis (IPF) compared to controls. They evaluated AZT's effects using RT-qPCR, western blot, ELISA, and microarray assays. The results showed that AZT reduces expression of pro-fibrotic genes in IPF fibroblasts more than in control fibroblasts. This suggests AZT has enhanced anti-fibrotic effects on IPF fibroblasts.